Clinical Trials

550 enrolled

Stomach Neoplasms

NCT06361888 2025-12-30

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Phase 2/3 Recruiting

502 enrolled

Pancreatic Neoplasms

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT06869226 2025-10-02

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

283 enrolled

Esophageal Neoplasms

NCT07100392 2025-08-17

LEAF-02

141 enrolled

Carcinoma, Hepatocellular

NCT07105748 2025-08-17

TASK-05

45 enrolled

Liver Neoplasms

NCT07057089 2025-08-14

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

90 enrolled

Locally Advanced Rectal Cancer

NCT05713994 2025-03-25

CCGLC-001

Recruiting

300 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04299581 2025-02-27

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

25 enrolled

Cholangiocarcinoma

NCT06333561 2025-02-06

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Recruiting

300 enrolled

Carcinoma, Hepatocellular

NCT05218889 2024-12-31

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Phase 1/2 Recruiting

90 enrolled

Pancreatic Neoplasms

NCT05613478 2024-12-31

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

130 enrolled

Carcinoma, Hepatocellular

NCT06654297 2024-12-11

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

Phase 1 Recruiting

6 enrolled

Esophageal Squamous Cell Carcinoma

NCT06711471 2024-12-02

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

31 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT06061276 2024-09-23

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Phase NA Recruiting

40 enrolled

Carcinoma, Hepatocellular, Liver Diseases

NCT05412589 2024-07-31

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

35 enrolled

Liver Neoplasms

NCT06516445 2024-07-24

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

33 enrolled

Colorectal Neoplasms

NCT06086457 2024-07-16

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

436 enrolled

Esophageal Neoplasms

NCT06485271 2024-07-03

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Recruiting

504 enrolled

Stomach Neoplasms

NCT06423170 2024-05-21

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

GastrointestinalGenitourinary

37 enrolled

Unresectable Gallbladder Cancer

NCT06148402 2024-05-13

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

30 enrolled

Colorectal Neoplasms

NCT06363825 2024-04-17

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

57 enrolled

Carcinoma, Hepatocellular

NCT04674956 2024-04-02

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

401 enrolled

Phase EARLY_PHASE1 Recruiting

Pancreatic Neoplasms

NCT06326736 2024-03-22

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

12 enrolled

Pancreatic Neoplasms

NCT05924997 2024-02-21

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Phase 1/2 Recruiting

52 enrolled

Carcinoma, Hepatocellular

NCT06176885 2023-12-27

FOBECAMS

36 enrolled

Colorectal Neoplasms

NCT05624099 2023-10-19

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

75 enrolled

Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms

NCT05202314 2023-02-21

NACSOC-02

Phase NA Recruiting

20 enrolled